SCHEMBL240794

SCHEMBL240794

CCCCc1cc(N)ccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.59
GABRD O14764 2/20 0.59
GABRA1 P14867 2/20 0.59
GABRB1 P18505 2/20 0.59
GABRG2 P18507 2/20 0.59
GABRB3 P28472 2/20 0.59
GABRA5 P31644 2/20 0.59
GABRA3 P34903 2/20 0.59
GABRA2 P47869 2/20 0.59
GABRB2 P47870 2/20 0.59
GABRA4 P48169 2/20 0.59
GABRE P78334 2/20 0.59
GABRA6 Q16445 2/20 0.59
GABRG1 Q8N1C3 2/20 0.59
GABRG3 Q99928 2/20 0.59
GABRQ Q9UN88 2/20 0.59
MAPT P10636 3/20 0.49
ALDH1A1 P00352 3/20 0.49
CYP3A4 P08684 2/20 0.49
KDM4E B2RXH2 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31117550 1.00 GABRP (0.59) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2481632 0.95 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9068637 0.94 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL6112733 0.94 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL9068780 0.94 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4327627 0.94 PPARA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1931833 0.90 MAPT (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29632107 0.90 ALDH1A1 (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL343331 0.90 ALDH1A1 (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29632227 0.90 ALDH1A1 (0.55) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1595936-B1 COMPOSITION FOR EXTERNAL USE VITAMIN C60 BIORES CORP (JP) 2011-10-19 EP claimed
US-20060110743-A1 Drug evolution: drug design at hot spots KONISHI YASUO 2006-05-25 US claimed
US-20050008570-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-01-13 US claimed
EP-1360485-A2 DIAGNOSTIC METHODS FOR POMPE DISEASE AND OTHER GLYCOGEN STORAGE DISEASES DUKE UNIVERSITY (US) 2003-11-12 EP claimed
WO-2002095393-A2 DRUG EVOLUTION: DRUG DESIGN AT HOT SPOTS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2002-11-28 WO claimed
US-20020102737-A1 Diagnostic methods for pompe disease and other glycogen storage diseases DUKE UNIVERSITY 2002-08-01 US claimed
WO-2001094941-A2 DIAGNOSTIC METHODS FOR POMPE DISEASE AND OTHER GLYCOGEN STORAGE DISEASES UNIV DUKE (US) 2001-12-13 WO claimed
US-6017961-A Ketamine and n-butyl-p-aminobezoate in PLO DISCOVER GROWTH FUND, LLC (VI) 2000-01-25 US claimed
EP-0590024-B1 TOPICAL COMPOSITION ENHANCING HEALING OF HERPES LESIONS VIRO TEX CORP (US) 1997-05-02 EP claimed
EP-0650511-A4 PHOTOTRANSCHROMIC INK. XYTRONYX INC (US) 1996-04-10 EP claimed
EP-0650511-A1 PHOTOTRANSCHROMIC INK XYTRONYX, INC. (US) 1995-05-03 EP claimed
US-5296275-A Water soluble nonionic resin carrier, a light sensitive compound which colors in response to protons, wetting agents, thickeners and flow aids XYTRONYX, INC. (US) 1994-03-22 US claimed
WO-1994001503-A1 PHOTOTRANSCHROMIC INK XYTRONYX, INC. (US) 1994-01-20 WO claimed
EP-4626464-A1 FEXAMETHODS FOR TREATING INFANTILE-ONSET POMPE DISEASE IN PEDIATRIC PATIENTS Amicus Therapeutics, Inc. (US) 2025-10-08 EP disclosed
EP-4603589-A2 MICELLAR NANOPARTICLES AND USES THEREOF Biorchestra Co., Ltd. (KR) 2025-08-20 EP disclosed
EP-3990028-B1 MICELLAR NANOPARTICLES AND USES THEREOF BIORCHESTRA CO LTD (KR) 2025-06-04 EP disclosed
US-4259448-A HYDROPHOBIC CHROMATOGRAPHY NIPPON SODA COMPANY, LTD. (JP) 1981-03-31 US disclosed
WO-1980002643-A1 METHOD AND COMPOSITION FOR CONTROLLING CORNEAL HYDRATION HOLLES LAB INC (US) 1980-12-11 WO disclosed
US-4225675-A A WATER INSOLUBLE CARRIER BOUND TO A PHENYL AMINE NIPPON SODA COMPANY, LTD. (JP) 1980-09-30 US disclosed
US-4021471-A Formamidines useful as ultraviolet light absorbers GIVAUDAN CORPORATION (US) 1977-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008570-A1 Hydroxypyridonate and hydroxypyrimidinone chelating agents HAMP, GDI1, MPI GABRP 1842/4885GABRD 4295/4885GABRA1 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.